Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis from the JUPITER Trial

類似資料

• Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The JUPITER Trial
  著者:: Mora, Samia, 等
  出版事項: (2015)
• Response to letter regarding article, “High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy.”
  著者:: Mora, Samia, 等
  出版事項: (2014)
• Cholesterol Efflux Capacity, HDL Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
  著者:: Khera, Amit V., 等
  出版事項: (2017)
• Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial
  著者:: Akinkuolie, Akintunde O., 等
  出版事項: (2016)
• On-Treatment Non-HDL Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk after Treatment with Potent Statin Therapy: The JUPITER Trial
  著者:: Mora, Samia, 等
  出版事項: (2012)